...
首页> 外文期刊>Annals of the New York Academy of Sciences >Application of a New Classification to a Breast Tumor Series from a Population-Based Cancer Registry: Demographic, Clinical, and Prognostic Features of Incident Cases, Palermo Province, 2002-2004
【24h】

Application of a New Classification to a Breast Tumor Series from a Population-Based Cancer Registry: Demographic, Clinical, and Prognostic Features of Incident Cases, Palermo Province, 2002-2004

机译:基于人群的癌症登记系统在乳腺癌肿瘤系列分类中的新应用:事故病例的人口统计,临床和预后特征,巴勒莫省,2002-2004年

获取原文
获取原文并翻译 | 示例
           

摘要

A new classification based on gene expression profiling or immunohistochemical (IHC) characteristics may replace current histopathological classifications and predict better clinical outcomes. We used IHC markers to classify incident cases ascertained by the Palermo Breast Cancer Registry (2002-2004) into four subtypes: luminal-A (ER+ or PgR+ and HER2eu-); luminal-B (ER+ or PgR+, HER2eu+); basal-like (ER-, PgR-, HER2eu-); and HER2+/ER- (HER2eu+, ER-, PgR-). We evaluated HER2eu, ER and PgR in 1300/1985 (65%) cases. The most common IHC-subtype was luminal-A (68%), whereas luminal-B, basal-like, and HER2+/ER-accounted for 14%, 13%, and 5%, respectively. IHC-subtypes were not associated with tumor size, geographic location within the province, or menopause, but differed by NPI (P < 0.0001), grading (P < 0.0001), lymph-node involvement (P = 0.04), metastases (P = 0.04), and TNM stage (P = 0.04). Endocrine therapy was administered to 81% of 519 postmenopausal, luminal-A, and luminal-B cases and to 32% of 114 postmenopausal, basal-like, and HER2+/ER-cases.
机译:基于基因表达谱或免疫组化(IHC)特征的新分类可能会替代当前的组织病理学分类并预测更好的临床结果。我们使用IHC标记将巴勒莫乳腺癌登记处(2002-2004)确定的事件病例分为四个亚型:腔A型(ER +或PgR +和HER2 / neu-);腔B(ER +或PgR +,HER2 / neu +);基底样(ER-,PgR-,HER2 / neu-);和HER2 + / ER-(HER2 / neu +,ER-,PgR-)。我们在1300/1985年(65%)的病例中评估了HER2 / neu,ER和PgR。 IHC最常见的亚型是腔A,占68%,而腔B,基底样和HER2 + / ER分别占14%,13%和5%。 IHC亚型与肿瘤大小,省内地理位置或更年期无关,但在NPI(P <0.0001),分级(P <0.0001),淋巴结受累(P = 0.04),转移灶(P = 0.04)和TNM阶段(P = 0.04)。 519例绝经后,管腔A和B的患者接受内分泌治疗,114例绝经后,基底样和HER2 + / ER病例的内分泌治疗为32%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号